NCT06849401View on ClinicalTrials.gov

The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

October 31, 2026

Conditions
T-ALL
Interventions
BIOLOGICAL

VGO-Cs01p

Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)

All Listed Sponsors
collaborator

Shanghai Vitalgen BioPharma Co., Ltd.

INDUSTRY

lead

Shanghai Jiao Tong University School of Medicine

OTHER